Kidney function may affect how HRS-1893 works in heart disease

NCT ID NCT06775834

Completed Knowledge-focused Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study looked at how HRS-1893 tablets are processed in people with mild or moderate kidney impairment compared to healthy subjects. The goal was to understand dosing needs for patients with hypertrophic cardiomyopathy who also have kidney issues. Twenty-four adults took part, and researchers measured drug levels in the blood and urine, along with safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1893 tablets
What this could lead to: If successful, this study could help doctors determine the right dose of HRS-1893 for people with kidney problems who have hypertrophic cardiomyopathy.
What could go wrong: This is a very early, small study (24 people) focused on drug levels and safety, not on treating the disease. It may not lead to any treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Show contact details

Locations

Sichuan Provincial People's Hospital

Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.